Melissa Bersanelli1,2, Sebastiano Buti1, Giuseppe Luigi Banna3, Ugo De Giorgi4, Alessio Cortellini5,6, Sara Elena Rebuzzi1,7, Marcello Tiseo1,2, Giuseppe Fornarini7, Francesca Mazzoni8, Stefano Panni9, Michele De Tursi10, Pietro Di Marino10, Sabrina Rossetti11, Ernesto Rossi12, Silverio Tomao13, Emmanuele De Luca14, Mariella Sorarù15, Claudia Mucciarini16, Francesco Atzori17, Leonardo La Torre18, Maria Giuseppa Vitale19, Valentino Martelli7, Pierangela Sepe20, Veronica Mollica21, Vanja Vaccaro22, Giovanni Schinzari12, Corrado Ficorella6,7, Francesco Massari21, Antonio Maestri18, Roberto Sabbatini19, Teodoro Sava15, Massimo Di Maio14, Elena Verzoni20, Giuseppe Procopio20, Diana Giannarelli23. 1. Medical Oncology Unit, University Hospital of Parma, Parma, Italy. 2. Department of Medicine & Surgery, University of Parma, Parma, Italy. 3. Medical Oncology, Cannizzaro Hospital, Catania, Italy. 4. Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. 5. Medical Oncology Unit, St Salvatore Hospital, L'Aquila, Italy. 6. Department of Biotechnological & Applied Clinical Sciences, St Salvatore Hospital, University of L'Aquila, L'Aquila, Italy. 7. Medical Oncology Unit 1, IRCCS Policlinico San Martino Hospital, Genova, Italy. 8. Medical Oncology Unit, Careggi University Hospital, Firenze, Italy. 9. Medical Oncology Unit, ASST - Istituti Ospitalieri Cremona Hospital, Cremona, Italy. 10. Department of Medical, Oral & Biotechnological Sciences & CeSI-MeT, University G. D'Annunzio, Chieti-Pescara, Italy. 11. Dipartimento Corp-S Assistenziale dei Percorsi Oncologici Uro-Genitale, S.S.D Oncologia Clinica Sperimentale Uro-Andrologica, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Napoli, Italy. 12. Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. 13. Department of Medical & Surgical Sciences & Biotechnology, University "La Sapienza", Latina, Italy. 14. Medical Oncology, Ordine Mauriziano Hospital, University of Turin, Torino, Italy. 15. Medical Oncology, Camposampiero Hospital, Padova, Italy. 16. Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy. 17. Medical Oncology, Department of Medical Sciences "M. Aresu", University Hospital & University of Cagliari, Cagliari, Italy. 18. Medical Oncology Department, Santa Maria della Scaletta Hospital, Imola, Italy. 19. Medical Oncology Unit, University Hospital of Modena, Modena, Italy. 20. Genito-Urinary Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori of Milan, Milano, Italy. 21. Division of Oncology, Sant'Orsola-Malpighi Hospital, Bologna, Italy. 22. Oncology Unit 1, Regina Elena National Cancer Institute, IRCCS, Rome, Italy. 23. Biostatistical Unit, Regina Elena National Cancer Institute, IRCCS, Rome, Italy.
Abstract
Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population.
Aim: INVIDIa was a retrospective, multicenter study, exploring the clinical efficacy of influenza vaccine in 300 cancer patients undergoing immunotherapy. Overall survival (OS) was immature at the initial report. Methods: We reported the final OS analysis from the original study population and within subgroups. Results: Both at the univariate and multivariate analysis, the occurrence of influenza syndrome (IS) was significantly related to better OS in the overall population (OR: 0.53 [95% CI: 0.32-0.88]; p = 0.01). In the lung cancer subgroup, receiving flu vaccine and/or developing IS was related to better OS (p = 0.04). Within elderly patients, the flu vaccine was the main variable for the relative OS advantage (p = 0.05). Conclusion: Receiving the flu vaccine and/or developing IS was related to better OS within the INVIDIa population.